GHTC honored Senator John Boozman (R-AR) and Senator Patty Murray (D-WA) for their leadership in supporting global health R&D with its 2020 Innovating for Impact Awards, which celebrate the US policymakers and partnerships driving global health innovation. GHTC also recognized the CARB-X partnership for its progress in accelerating research to combat the urgent threat of drug-resistant bacteria.
Learn more
GHTC delivered a statement at the 148th session of the World Health Organization (WHO) Executive Board calling on WHO and member states to increase investment in R&D for affordable and accessible health technologies to fight antimicrobial resistance (AMR). The statement, issued through the Global Health Council, urges WHO and member states to advance policies and incentives to revitalize the fragile research pipeline, including supporting the Global Antibiotic Research and Development Partnership.
Learn more
GHTC submitted a statement to the 148th session of the World Health Organization (WHO) Executive Board commending WHO and member states on achieving progress toward global immunization targets and calling for greater investment in R&D for vaccine technologies and capacity-building for vaccine uptake, noting continued gaps in coverage. The statement, issued through the Global Health Council, calls on WHO and member states to address the full spectrum of immunization innovations, from administration to storage to service delivery.
Learn more
GHTC delivered a statement at the 148th session of the World Health Organization (WHO) Executive Board calling on WHO to address leading barriers to innovation of and access to essential health products. The statement, issued through the Global Health Council, urges WHO and member states to bolster regulatory capacity and harmonization, strengthen the Global Observatory on Health Research and Development, develop target product profiles for needed tools, and expand the Essential Diagnostics List as part of this effort.
Learn more
An op-ed from GHTC director Jamie Bay Nishi, reflecting on findings from GHTC's report Pain Points and Potential: How COVID-19 is Reshaping Global Health R&D, was featured in Health Policy Watch.
View
GHTC urges Congress to pass a COVID-19 emergency supplemental bill that includes at least $11 billion for global health programs to support the international response to the pandemic, underscoring the need for dedicated funding to USAID and CEPI.
Learn more
The strong foundation of global health R&D that greatly accelerated the development of COVID-19 innovations is now being weakened by pandemic pressures that are diverting funding and expertise away from other dangerous diseases and putting clinical trials and scientific endeavors around the world on indefinite hold. That’s a key conclusion of a new report released today from GHTC.
Learn more
GHTC honored Senator John Boozman (R-AR) and Senator Patty Murray (D-WA) for their leadership in supporting global health R&D with its 2020 Innovating for Impact Awards, which celebrate the US policymakers and partnerships driving global health innovation. GHTC also recognized the CARB-X partnership for its progress in accelerating research to combat the urgent threat of drug-resistant bacteria.
Learn more
GHTC strongly endorses yesterday’s declaration from G20 health ministers elevating the importance of investments in new tools and technologies to fight infectious diseases—work that has provided a strong foundation for combatting the COVID-19 pandemic and can be broadly beneficial in confronting a wide range of other threats.
Learn more
Global Health Now featured a commentary, authored by GHTC Director Jamie Bay Nishi, highlighting key findings from GHTC's report Pain Points and Potential: How COVID-19 is Reshaping Global Health R&D.
View
Devex cited a report released by GHTC assessing the impact of the COVID-19 pandemic on global health R&D.
View
Health Europa covered a report released by GHTC assessing the impact of the COVID-19 pandemic on global health R&D.
View
ScienceBoard.net, a publication covering life science and pharmaceutical trends, reported on a findings from GHTC's report, Pain Points and Potential: How COVID-19 is Reshaping Global Health R&D.
View
GHTC delivered a statement at the 148th session of the World Health Organization (WHO) Executive Board calling on WHO and member states to increase investment in R&D for affordable and accessible health technologies to fight antimicrobial resistance (AMR). The statement, issued through the Global Health Council, urges WHO and member states to advance policies and incentives to revitalize the fragile research pipeline, including supporting the Global Antibiotic Research and Development Partnership.
Learn more
GHTC submitted a statement to the 148th session of the World Health Organization (WHO) Executive Board commending WHO and member states on achieving progress toward global immunization targets and calling for greater investment in R&D for vaccine technologies and capacity-building for vaccine uptake, noting continued gaps in coverage. The statement, issued through the Global Health Council, calls on WHO and member states to address the full spectrum of immunization innovations, from administration to storage to service delivery.
Learn more
GHTC delivered a statement at the 148th session of the World Health Organization (WHO) Executive Board calling on WHO to address leading barriers to innovation of and access to essential health products. The statement, issued through the Global Health Council, urges WHO and member states to bolster regulatory capacity and harmonization, strengthen the Global Observatory on Health Research and Development, develop target product profiles for needed tools, and expand the Essential Diagnostics List as part of this effort.
Learn more
As a member of the Global Health Council's (GHC) delegation for the second session of the 73rd World Health Assembly (WHA), GHTC joined GHC in its statement from civil society urging continued investments in R&D to achieve universal health coverage (UHC), advance immunization coverage through the Global Vaccine Action Plan, and close the US$1.3 billion funding gap for tuberculosis R&D.
Learn more
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Virtual
View
The International AIDS Society
Virtual
View
Japan Alliance on Global Neglected Tropical Diseases, Global Health Innovative Technology Fund
Virtual
View
The United Nations Association of the USA
Virtual
View
Marissa Chmiola
Communications Officer
Global Health Technologies Coalition
(202) 540-4414
mchmiola@ghtcoalition.org